EW (Edwards Lifesciences Corporation) יחס מהיר

Risks for Edwards Lifesciences (EW) are linked to a narrow portfolio of cardiac implants and the potential cancellation of high-cost surgeries. However, international sales and a diverse range of monitoring systems mitigate regulatory complexities. This daily chart from the GURU.Markets platform reflects the dynamics of the strict liquidity ratio, where the value 3.59 captures the metric level, confirming the company's leadership in the transcatheter valve niche without resorting to price dumping.

A defensive portfolio requires strict solvency control by filtering out illiquid assets. This metric assesses the ability to settle current debts using exclusively cash and accounts receivable, excluding inventory. This is critical for Edwards Lifesciences (EW), as massive R&D investments necessitate constant access to liquid funds. The trend in the quick ratio confirms the financial stability of this innovation leader.